Ad-p53 enhances the sensitivity of triple-negative breast cancer MDA-MB-468 cells to the EGFR inhibitor gefitinib

• Published in: Oncology reports Vol. 33; no. 2; pp. 526 - 532
• Main Authors: WANG, XINZHAO, SONG, HONGKUAN, YU, QIAN, LIU, QI, WANG, LEILEI, LIU, ZHAOYUN, YU, ZHIYONG
• Format: Journal Article
• Language: English
• Published: Greece D.A. Spandidos 01.02.2015; Spandidos Publications; Spandidos Publications UK Ltd
• Subjects: Adenoviridae - genetics; Adenoviruses; Animals; Antineoplastic Agents - administration & dosage; Antineoplastic Agents - pharmacology; Apoptosis; Binding sites; Breast cancer; Cancer therapies; Cell cycle; Cell Line, Tumor; Cell Proliferation - drug effects; DNA repair; Dosage and administration; Drug Synergism; Drug therapy; EGFR; Female; Gefitinib; Gene Expression Regulation, Neoplastic - drug effects; Genetic Vectors - genetics; Genetic Vectors - metabolism; Growth factors; Health aspects; Humans; Inhibitor drugs; Kinases; Lung cancer; MDA-MB-468 cells; Medical prognosis; Mice; p53; Phosphatidylinositol 3-Kinase - metabolism; PI3K/Akt; Proteins; Quinazolines - administration & dosage; Quinazolines - pharmacology; Signal Transduction - drug effects; Studies; Targeted cancer therapy; targeted therapy; Triple Negative Breast Neoplasms - drug therapy; Triple Negative Breast Neoplasms - genetics; Triple Negative Breast Neoplasms - pathology; triple-negative breast cancer; Tumor proteins; Tumor Suppressor Protein p53 - genetics; Tumor Suppressor Protein p53 - metabolism; Tumors; Xenograft Model Antitumor Assays; United States > US

Triple-negative breast cancer (TNBC) accounts for 20% of all molecular subtypes of breast cancer. Neither endocrine nor anti-HER2 molecular targeting treatment yield promising results. At present, epidermal growth factor receptor (EGFR) inhibitor, as a single agent, is unable to obtain encouraging r...